MyoKardia Presents 36-week Data from PIONEER-OLE Study of Mavacamten at the European Society of Cardiology Congress 2019
31 août 2019 05h00 HE
|
MyoKardia, Inc.
Durability of Mavacamten's Safety and Efficacy Profile Demonstrated through Nine Months in this Study of Patients with Symptomatic, Obstructive HCM Statistically Significant Changes in Key Biomarkers...
MyoKardia Announces Abstracts Selected for Presentation at the European Society of Cardiology Congress 2019
26 août 2019 08h30 HE
|
MyoKardia, Inc.
SOUTH SAN FRANCISCO, Calif., Aug. 26, 2019 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK) today announced the presentation of three abstracts at the upcoming European Society of Cardiology (ESC)...